India's Aurobindo Pharma gains on US FDA nod for anti-cancer tablet Dasatinib
View all comments(0)
Shares of drug maker Aurobindo Pharma ARBN.NS rise as much as 4.2% to 1,237.70 rupees
Unit receives U.S. FDA's approval for Dasatinib tablets
Adds, Dasatinib, used as anti-cancer medication, is expected to be launched in Q1FY26
Stock top gainer in Nifty Pharma Index .NIPHARM which is up 1.1%
Share price above 50-day, 100-day and 200-day exponential moving averages
Avg rating of 25 analysts equivalent of "buy", median PT is 1,463 rupees - data compiled by LSEG
Stock last up 4.1%, cutting YTD loss to 7.3%
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.